Atect Corp operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Atect Corp with three other
pharmaceutical manufacturers in Asia:
Ina Research Incorporation
sales of 2.30 billion Japanese Yen [US$20.76 million]
of which 86%
was Non-clinical business),
Hester Pharmaceuticals Limited
(1.23 billion Indian Rupees [US$19.19 million]
of which 88%
was Poultry Vaccines), and
China Regenerative Medicine International Ltd
based in Hong Kong
(356.99 million Hong Kong Dollars [US$45.63 million]
of which 51%
was Medical Products and Equipment).
Atect Corp reported sales of ¥2.48 billion (US$22.45 million)
March of 2017.
a very small
increase of 0.4%
versus 2016, when the company's sales were ¥2.47 billion.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Atect Corp had sales
of ¥2.50 billion.
Sales of Semiconductor Material saw an increase
that was more than double the company's growth rate: sales were up
3.5% in 2017, from
¥793.50 million to ¥821.57 million.
Not all segments of Atect Corp experienced an increase in sales in 2017:
sales of Health Inspection Equipment fell 1.2% to ¥1.56 billion.
Atect Corp also experienced decreases in sales in
Pim (down 0.6% to ¥105.49 million)